In order to speed the development of precision medicine and benefit the cancer patient, the Belgium based nonprofit organization Oncidium is established since 2011. Oncidium takes the mission to support and accelerate the growth and the use of novel radiopharmaceuticals for cancer treatment, without the concern of source, skills and finance status.

Oncidium is dedicated to building up a network to popularize novel radiopharmaceuticals by providing patients the access to local health centers which offer diagnostic radiography for treatment. 18 experts from 11 countries have joined as Oncidium Ambassadors, they have united and demonstrated their commitment to increasing awareness of novel radiopharmaceuticals through education, cancer organization partnership, domestic collaboration and information sharing

Dr. Ya-Yao Huang, the Ambassador of Oncidium in Taiwan is also the chairwoman of pharmaceutical technology committee at Society of Nuclear Medicine of Taiwan and adjunct assistant professor in the Institute of Medical Device and Imaging ,National Taiwan University College of Medicine. As the founder and CEO of Primo Biotechnology, Dr. Ya-Yao Huang leads the team to carry out Oncidium’s spirit and brings it to Taiwan. Primo Biotechnology not only actively participates in global radiopharmaceuticals collaborations but also takes what Taiwan has achieved in radiopharmaceuticals to the whole world.

Primo Biotechnology, is the startup biotechnology company composed of experts and elites from Taiwan, is committed to evolving precision medicine and benefiting all people in Asia. By collaborating with Oncidium, Dr. Ya-Yao Huang and her Primo Team are on a mission to overcome the previous challenges and bring the skills of radiopharmaceuticals to the world and let Asia shine. Read more about Primo